Quantcast
Last updated on April 24, 2014 at 11:39 EDT

Latest Pacira Pharmaceuticals Inc. Stories

2014-02-21 23:03:17

National Patient Safety Foundation Program Aligns Stakeholders from Across Health Care in a Unifying Mission Boston, MA (PRWEB) February 21, 2014 The National Patient Safety Foundation (NPSF), a central voice for patient safety since 1997, is pleased to announce that Pacira Pharmaceuticals, Inc., has joined the NPSF Patient Safety Coalition as an associate member. Pacira, located in New Jersey and California, is a specialty pharmaceutical company focused on the development of new products...

2013-10-23 08:30:04

NEW YORK, October 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), pSivida Corp. (NASDAQ: PSDV), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full...

2012-10-13 04:04:32

IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management. Online (PRWEB) October 11, 2012 PARSIPPANY, N.J.-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary endpoints–cost, opioid consumption and hospital length of...

2012-05-10 06:27:20

ALEXANDRIA, Va., May 10, 2012 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced that it closed a $27.5 million senior secured term loan with Pacira Pharmaceuticals ("Pacira"). Proceeds of the loan are being used to refinance existing debt and for general working capital. "Oxford is very pleased to provide capital to Pacira, a company whose management team has been successful...

2011-12-19 05:30:00

PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL(TM) (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia. The results, which demonstrate statistically significantly...

2011-12-05 05:30:00

PARSIPPANY, N.J., Dec. 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced new data gleaned from a national database of patients from 381 U.S. hospitals who underwent common hospital-based surgical procedures and received opioids for postsurgical pain management. The data demonstrate that opioid-related adverse events (ORAEs) are associated with more than a $1,000 increase in hospitalization cost and more than a day increase in length of hospital stay...

2011-11-22 05:30:00

PARSIPPANY, N.J., Nov. 22, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced it has completed a follow-on offering of 7,000,000 shares of its common stock, at a price to the public of $6.50 per share. Pacira also announced that its underwriters have exercised their over-allotment option in full to purchase an additional 1,050,000 shares of common stock, also at $6.50 per share. All of the 8,050,000 shares are...

2011-11-16 05:30:00

PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses....

2011-10-31 05:32:00

PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL(TM) (bupivacaine liposome injectable suspension) and the commercial strategy to support the product launch. "With the broad postsurgical pain management label granted by the FDA,...

2011-10-31 05:30:00

PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL(TM) (bupivacaine liposome injectable suspension) 1.3% for administration into the surgical site to produce postsurgical analgesia. In a pivotal hemorrhoidectomy trial of EXPAREL compared to placebo, where all patients with inadequate pain control received opioids for rescue pain relief, EXPAREL demonstrated significant...